Max Planck Insitute of Psychiatry
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Falkai, Peter
NCT02926859: Enhancing Recovery in Early Schizophrenia

Recruiting
2
180
Europe
Cannabidiol as add-on, Placebo as add-on
Central Institute of Mental Health, Mannheim
Schizophrenia
12/24
12/25
DECIDE, NCT06396312: Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression

Recruiting
N/A
130
Europe
Max-Planck-Institute of Psychiatry
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms, Depressive Disorder, Treatment-Resistant, Class I or II, Depressive Disorder, Major, Moderate, Depressive Disorder, Major, Severe
04/28
04/29
BrainTrain, NCT05956327: Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training

Recruiting
N/A
156
Europe
Aerobic Endurance Training, Flexibility, strengthening and balance training
LMU Klinikum, German Research Foundation
Schizophrenia, Neuronal Plasticity, Exercise
09/26
09/26
Fischer, Laura
NCT02134301 / 2013-005415-26: Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Recruiting
1
52
US
Oritavancin
Melinta Therapeutics, LLC
Gram Positive Bacterial Infections
12/24
06/25
TANGOKIDS, NCT02687906 / 2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Recruiting
1
67
US
Vabomere, Combination meropenem and vaborbactam, carbapenem and beta-lactamase inhibitor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Department of Health and Human Services
Bacterial Infections
12/24
06/25
PRoART, NCT06185062: Pelvic Cancer Registry for Online Adapted Radiotherapy

Recruiting
N/A
846
Europe
University Medical Center Goettingen
Pelvic Tumor, Thoracic Tumor
09/29
04/30
PROJECTION, NCT04246203: Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

Recruiting
N/A
200
Europe
Liquid Biopsy
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche
Pancreas Cancer
12/24
12/25
DECIDE, NCT06396312: Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression

Recruiting
N/A
130
Europe
Max-Planck-Institute of Psychiatry
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms, Depressive Disorder, Treatment-Resistant, Class I or II, Depressive Disorder, Major, Moderate, Depressive Disorder, Major, Severe
04/28
04/29
SCC-BAREDU, NCT05396794: Bariatric Education for Women With Obesity and Endometrial Cancer

Recruiting
N/A
80
US
Standard weight loss education, Standard weight loss education + Educational Video
University of Oklahoma
Obesity, Endometrial Cancer, Bariatric Surgery Candidate
08/25
08/26
Raabe, Florian
DECIDE, NCT06396312: Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression

Recruiting
N/A
130
Europe
Max-Planck-Institute of Psychiatry
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms, Depressive Disorder, Treatment-Resistant, Class I or II, Depressive Disorder, Major, Moderate, Depressive Disorder, Major, Severe
04/28
04/29

Download Options